[1]王瑶,李铁鹏,何美颉,等.肿瘤免疫检查点抑制剂联合过继性细胞免疫治疗研究进展[J].新乡医学院学报,2022,39(10):988-991.[doi:10.7683/xxyxyxb.2022.10.017]
　WANG Yao,LI Tiepeng,HE Meijie,et al.Research progress of tumor immune checkpoint inhibitor combined with adoptive cellular immunotherapy[J].Journal of Xinxiang Medical University,2022,39(10):988-991.[doi:10.7683/xxyxyxb.2022.10.017]
点击复制

肿瘤免疫检查点抑制剂联合过继性细胞免疫治疗研究进展
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
39
期数:
2022年10
页码:
988-991
栏目:
综述
出版日期:
2022-10-05

文章信息/Info

Title:
Research progress of tumor immune checkpoint inhibitor combined with adoptive cellular immunotherapy
作者:
王瑶1; 2; 李铁鹏1; 何美颉1; 高全立1
（1.郑州大学附属肿瘤医院暨河南省肿瘤医院免疫治疗科，河南　郑州　450008；2.新乡医学院基础医学院，河南　新乡　453003）
Author(s):
WANG Yao1; 2; LI Tiepeng1; HE Meijie1; GAO Quanli1
(1.Department of Immunotherapy,Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Zhengzhou 450008,Henan Province,China;2.Basic Medical College of Xinxiang Medical University,Xinxiang 453003,Henan Province,China)
关键词:
肿瘤免疫治疗; 免疫检查点抑制剂; 过继性细胞免疫治疗
Keywords:
tumor immunotherapy; immune checkpoint inhibitor; adoptive cellular immunotherapy
分类号:
R979.1
DOI:
10.7683/xxyxyxb.2022.10.017
文献标志码:
A
摘要:
免疫检查点抑制剂的应用为肿瘤临床治疗提供了新方法，然而，仍有大量患者难以从免疫检查点抑制剂治疗中获益。在免疫检查点抑制剂的基础上探索新的联合治疗方案是当前肿瘤治疗的一大热点，其中，过继性细胞免疫治疗是联合免疫检查点抑制剂治疗肿瘤的重要选择。本文对肿瘤免疫检查点抑制剂联合过继性细胞免疫治疗的最新研究进展进行综述。
Abstract:
The application of immune checkpoint inhibitor provides a new method for tumor clinical treatment,however,a large number of patients still struggle to benefit from immune checkpoint inhibitor therapy.Exploring new combination therapy options based on immune checkpoint inhibitors is a hot spot in current tumor therapy.Among them,adoptive cellular immunotherapy is an important option for the treatment of tumors in combination with immune checkpoint inhibitors.This article reviews the latest research progress of immune checkpoint inhibitors combined with adoptive cellular immunotherapy for tumors.

参考文献/References:

［1］　KENNEDY L B,SALAMA A K S.A review of cancer immunotherapy toxicity［J］.CA Cancer J Clin,2020,70(2):6-104.
［2］　COUZIN-FRANKEL J.Breakthrough of the year 2013.Cancer immunotherapy［J］.Science,2013,342(6165):1432-1433.
［3］　MARIN-ACEVEDO J A,DHOLARIA B,SOYANO A E,et al.Next generation of immune checkpoint therapy in cancer:new developments and challenges［J］.J Hematol Oncol,2018,11(1):39.
［4］　KONE,BENHAR I.Immune checkpoint inhibitor combinations:current efforts and important aspects for success［J］.Drug Resist Updat,2019,45:13-29.
［5］　TUMEH P C,HARVIEW C L,YEARLEY J H,et al.PD-1 blockade induces responses by inhibiting adaptive immune resistance［J］.Nature,2014,515(7528):568-571.
［6］　CHEN C L,PAN Q Z,WENG D S,et al.Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors［J］.Oncoimmunology,2018,7(4):e1417721.
［7］　YUAN Z,YANG H,WEI Y.Combined induction with anti-PD-1 and anti-CTLA-4 antibodies provides synergistic antitumor effects in DC-CIK cells in renal carcinoma cell lines［J］.Int J Clin Exp Pathol,2019,12(1):123-132.
［8］　李雪芹,王少彬,陈俊辉.肿瘤特异性过继T细胞免疫治疗技术进展［J］.医学综述,2017,23(10):1935-1939.
LI X Q,WANG S B,CHEN J H.Technological advances in adoptive cellular immunotherapy using tumor specific T lymphocytes［J］.Med Recap,2017,23(10):1935-1939.
［9］　SONG Y,LIU Q,ZUO T,et al.Combined antitumor effects of anti-EGFR variant Ⅲ CAR-T cell therapy and PD-1 checkpoint blockade on glioblastoma in mouse model［J］.Cell Immunol,2020,352:104112.
［10］　HAY K A,GAUTHIER J,HIRAYAMA A V,et al.Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR-T cells ［J］.Blood,2019,133(15):1652-1663.
［11］　REN P P,LI M,LI T F,et al.Anti-EGFRvIII chimeric antigen receptor-modified T cells for adoptive cell therapy of glioblastoma［J］.Curr Pharm Des,2017,23(14):2113-2116.
［12］　ZHANG R,DENG Q,JIANG Y Y,et al.Effect and changes in PD-1 expression of CD19 CAR-T cells from T cells highly expressing PD-1 combined with reduceddose PD-1 inhibitor［J］.Oncol Rep,2019,41(6):3455-3463.
［13］　JOHN L B,DEVAUD C,DUONG C P,et al.Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells［J］.Clin Cancer Res,2013,9(20):5636-5646.
［14］　CHONG E A,MELENHORST J J,LACEY S F,et al.PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells:refueling the CAR ［J］.Blood,2017,129 (8):1039 -1041.
［15］　ADUSUMILLI P S,ZAUDERER M G,RIVIERE I,et al.A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease,in combination with the anti-PD-1 agent pembrolizumab ［J］.Cancer Discov,2021,11(11):2748-2763.
［16］　RAMOS-CASALS M,BRAHMER J R,CALLAHAN M K,et al.Immune-related adverse events of checkpoint inhibitors［J］.Nat Rev Dis Primers,2020,6(1):38.
［17］　RAFIQ S,YEKU O O,JACKSON H J,et al.Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo［J］.Nat Biotechnol,2018,36(9):847-856.
［18］　董强刚.抗原特异性T细胞过继免疫治疗的临床研究:现状与前景展望［J］.中国细胞生物学学报,2018,40(S1):2269-2280.
DONG Q G. Adoptive immunotherapy with antigen-specific T cells in clinic:current advances and future directions［J］.Chin J Cell Biol,2018,40(13):2269-2280
［19］　RAMACHANDRAN I,LOWTHER D E,DRYER-MINNERLY R,et al.Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma［J］.J Immunother Cancer,2019,7(1):276.
［20］　MATSUZAKI J,GNJATIC S,MHAWECH-FAUCEGLIA P,et al.Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer［J］.Proc Natl Acad Sci U S A,2010,107(17):7875-7880.
［21］　PENG W,LIU C,XU C,et al.PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines［J］.Cancer Res,2012,72(20):5209-5218.
［22］　MORGAN R A,CHINNASAMY N,ABATE-DAGA D,et al.Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy［J］.J Immunother,2013,36(2):133-151.
［23］　HIRAYAMA A V,TURTLE C J.Toxicities of CD19 CAR-T cell immunotherapy［J］.Am J Hematol,2019,94(S1):S42-S49.
［24］　ROHAAN M W,VAN DEN BERG J H,KVISTBORG P,et al.Adoptive transfer of tumor-infiltrating lymphocytes in melanoma:a viable treatment option［J］.J Immunother Cancer,2018,6(1):102.
［25］　DURAISWAMY J,KALUZA K M,FREEMAN G J,et al.Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors［J］.Cancer Res,2013,73(12):3591-3603.
［26］　TENG M W L,NGIOW S F,RIBAS A,et al.Classifying cancers rased on T-cell infiltration and PD-L1［J］.Cancer Res,2015,75(11):2139-2145.
［27］　NGUYEN L T,SAIBIL S D,SOTOV V,et al.Phase Ⅱ clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2［J］.Cancer Immunol Immunother,2019,68(5):773-785.
［28］　BESSER M J,SHAPIRA-FROMMER R,ITZHAKI O,et al.Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma:intent-to-treat analysis and efficacy after failure to prior immunotherapies［J］.Clin Cancer Res,2013,19(17):4792-4800.
［29］　DUDLEY M E,GROSS C A,LANGHAN M M,et al.CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma［J］.Clin Cancer Res,2010,16(24):6122-6131.
［30］　BARRY K C,HSU J,BROZ M L,et al.A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments［J］.Nat Med,2018,24(8):1178-1191.
［31］　HSU J,HODGINS J J,MARATHE M,et al.Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade［J］.J Clin Invest,2018,128(10):4654-4668.
［32］　KON E,BENHAR I.Immune checkpoint inhibitor combinations:current efforts and important aspects for success［J］.Drug Resist Updat,2019,45:13-29.
［33］　LIN M,LUO H,LIANG S,et al.Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients［J］.J Clin Invest,2020,130(5):2560-2569.
［34］　CICHOCKI F,BJORDAHL R,GAIDAROVA S,et al.iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy［J］.Sci Transl Med,2020,12(568):5618.
［35］　MATA-MOLANES J J,SUREDA GONZALEZ M,VALENZUELA JIMENEZ B,et al.Cancer immunotherapy with cytokine-induced killer cells［J］.Target Oncol,2017,12(3):289-299.
［36］　ZHANG Y,ELLINGER J,RITTER M,et al.Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma［J］.Cancers (Basel),2020,12(9):2471.
［37］　ZHANG Y,SCHMIDT-WOLF I G H.Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy［J］.J Cell Physiol,2020,235(12):9291-9303.
［38］　ZHANG L,WANG J,WEI F,et al.Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients［J］.Oncotarget,2016,7(28):43604-43615.
［39］　DAI C,LIN F,GENG R,et al.Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer［J］.Oncotarget,2016,7(9):10332-10344．
［40］　HAN Y,MU D,LIU T,et al.Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD-1 blocking antibodies in patients with advanced non-small cell lung cancer:a preliminary study［J］.Thorac Cancer,2021,12(2):145-152.
［41］　ZHAO L,HAN L,ZHANG Y,et al.Combination of PD-1 blockade and RetroNectin?-activated cytokine-induced killer in preheavily treated non-small-cell lung cancer:a retrospective study［J］.Immunotherapy,2018,10(15):1315-1323.

相似文献/References:

[1]张世魁,李景艳,梅家转.NKG2D-NKG2D配体系统抗肿瘤作用研究进展[J].新乡医学院学报,2017,34(1):079.[doi:10.7683/xxyxyxb.2017.01.023]
[2]杨　赟,柳　鹏,张子恒,等.以表皮生长因子受体ErbB为靶点的抗体药物研究进展[J].新乡医学院学报,2017,34(10):871.[doi:10.7683/xxyxyxb.2017.10.002]
[3]黄玉斌,刘　霄,徐翠香,等.胃癌干细胞和免疫检查点抑制剂治疗胃癌研究进展[J].新乡医学院学报,2022,39(5):486.[doi:10.7683/xxyxyxb.2022.05.017]
　HUANG Yubin,LIU Xiao,XU Cuixiang,et al.Research progress of gastric cancer stem cells and immune checkpoint inhibitors therapy for gastric cancer[J].Journal of Xinxiang Medical University,2022,39(10):486.[doi:10.7683/xxyxyxb.2022.05.017]
[4]张杰,魏渼倬,赵玲,等.外周血中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值与接受免疫检查点抑制剂治疗食管鳞状细胞癌患者预后的相关性[J].新乡医学院学报,2023,40(7):621.[doi:10.7683/xxyxyxb.2023.07.004]
　ZHANG Jie,WEI Meizhuo,ZHAO Ling,et al.Correlation of neutrophil-to-lymphocyte ratio,platelet-to-lymphocyte ratio and the prognosis of esophageal squamous cell carcinoma treated with immune checkpoint inhibitors[J].Journal of Xinxiang Medical University,2023,40(10):621.[doi:10.7683/xxyxyxb.2023.07.004]

更新日期/Last Update: 2022-10-05